16/12 update: XRO is trading at $110, and we’re monitoring price action for increased buying interest and a close above the 10-day average.
Xero Add to your watchlist.
You're not a member! Trial today
1H26: Overall, a weaker result vs market expectations despite EBITDA a slight beat. EBITDA-capex cash flow came in -6% below consensus. Whilst operating costs have seen good control, capex spend is trending up due to investments in new AI capabilities.
Look for buying interest to rebuild, and we’ll revisit the entry point once the price action is above the 10-day average.
